医学
抗血栓
重症监护医学
肝素
部分凝血活酶时间
止血
血栓形成
抗凝剂
药理学
外科
内科学
血小板
作者
Michael Safani,Steve Appleby,Ryan G. Chiu,Emmanuel J. Favaloro,Emanuel T Ferro,Jimmy Johannes,Milan Sheth
标识
DOI:10.1080/17474086.2023.2169126
摘要
Unfractionated heparin remains the most widely used agent in the prevention and acute treatment of thrombosis. Pharmacological complexities of this intriguing agent mandate frequent monitoring of its anticoagulant properties to maintain safe and effective hematological outcomes. Although activated partial thromboplastin time has been the standard test to monitor unfractionated heparin therapy for many decades, the anti-Xa assay has emerged as a substitute or adjunct in many institutions.This brief report outlines the key features of anti-Xa assay in monitoring unfractionated heparin in acute management of thrombosis in various contemporary settings, with emphasis on evidence for clinical outcomes. PubMed.gov database was utilized to obtain the pertinent literature.The anti-Xa activity is primarily a reflection of UFH concentration and does not account for other hematological variables frequently present in contemporary anticoagulation management. The advantage of the anti-Xa assay in monitoring UFH therapy is predicated upon its limitations to account for global physiological hemostasis. There are significant disease and drug interactions that may potentially result in false in-vitro analysis of anti-Xa activity. Routine application of the anti-Xa assay is not evidence-based at this time.
科研通智能强力驱动
Strongly Powered by AbleSci AI